Martin H. Huber Jr.
CIK: 0001653276
Martin H. Huber Jr.'s purchase track record
Martin H. Huber Jr. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/19/2025 | SNDX | $45K | +70.7% | +84.7% | +11.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SNDX | ▲ Buy | Grant | 24,000 | $0 | 2/4/2026 | View on chart |
| SNDX | ▲ Buy | Open Market | 5,000 | $45K | 5/19/2025 | View on chart |
| SNDX | ▲ Buy | Grant | 25,000 | $0 | 2/5/2025 | View on chart |
| SNDX | ▲ Buy | Grant | 17,000 | $0 | 2/7/2024 | View on chart |
| SNDX | ▲ Buy | Grant | 16,000 | $0 | 2/2/2023 | View on chart |
| SNDX | ▲ Buy | Grant | 16,000 | $0 | 2/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
SNDX Drops After Axatilimab IPF Trial Misses Endpoint
Syndax Pharmaceuticals stock fell sharply after topline results from the MAXPIRe Phase 2 trial showed axatilimab did not meet its primary endpoint in idiopathic pulmonary fibrosis. The negative data triggered a significant selloff, with the stock dropping as much as 16% in after-hours trading. While some analysts maintain price targets, the trial outcome has raised questions about the drug's potential in this indication.
SNDX Drops After Axatilimab IPF Trial Misses Endpoint. Syndax Pharmaceuticals stock fell sharply after topline results from the MAXPIRe Phase 2 trial showed axatilimab did not meet its primary endpoint in idiopathic pulmonary fibrosis. The negative data triggered a significant selloff, with the stock dropping as much as 16% in after-hours trading. While some analysts maintain price targets, the trial outcome has raised questions about the drug's potential in this indication.